{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:42:14Z","timestamp":1783489334672,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06335-2","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:26:48Z","timestamp":1759811208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan"],"prefix":"10.1007","volume":"151","author":[{"given":"Wen-Kuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Fu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jer","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Hsien","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chang","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-0828","authenticated-orcid":false,"given":"See-Tong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-5496","authenticated-orcid":false,"given":"Dong-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"6335_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/jc.2011-2189","volume":"97","author":"G Attard","year":"2012","unstructured":"Attard G, Reid AH, Auchus RJ et al (2012) Clinical and biochemical consequences of CYP17A1 Inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97:507\u2013516. https:\/\/doi.org\/10.1210\/jc.2011-2189","journal-title":"J Clin Endocrinol Metab"},{"key":"6335_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"key":"6335_CR3","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA et al (2023) Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat 68:100962. https:\/\/doi.org\/10.1016\/j.drup.2023.100962","journal-title":"Drug Resist Updat"},{"key":"6335_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/jpet.120.265868","volume":"374","author":"EJY Cheong","year":"2020","unstructured":"Cheong EJY, Nair PC, Neo RWY et al (2020) Slow-, tight-binding Inhibition of CYP17A1 by abiraterone redefines its kinetic selectivity and dosing regimen. J Pharmacol Exp Ther 374:438\u2013451. https:\/\/doi.org\/10.1124\/jpet.120.265868","journal-title":"J Pharmacol Exp Ther"},{"key":"6335_CR5","doi-asserted-by":"publisher","first-page":"100887","DOI":"10.1016\/j.eclinm.2021.100887","volume":"36","author":"EB Cone","year":"2021","unstructured":"Cone EB, Reese S, Marchese M, Nabi J, McKay RR, Kilbridge KL, Trinh QD (2021) Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study. EClinicalMedicine 36:100887. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100887","journal-title":"EClinicalMedicine"},{"key":"6335_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/pros.24510","volume":"83","author":"MM Conover","year":"2023","unstructured":"Conover MM, Weaver J, Fan B, Leitz G, Richarz U, Li Q, Gifkins D (2023) Cardiovascular outcomes among patients with castration-resistant prostate cancer: a comparative safety study using US administrative claims data. Prostate 83:729\u2013739. https:\/\/doi.org\/10.1002\/pros.24510","journal-title":"Prostate"},{"key":"6335_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard First-Line therapy in metastatic prostate cancer. N Engl J Med 381:121\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1903835","journal-title":"N Engl J Med"},{"key":"6335_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"key":"6335_CR9","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","volume":"74","author":"L Fardet","year":"2014","unstructured":"Fardet L, Feve B (2014) Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs 74:1731\u20131745. https:\/\/doi.org\/10.1007\/s40265-014-0282-9","journal-title":"Drugs"},{"key":"6335_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"key":"6335_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/0284186X.2021.1885058","volume":"60","author":"G George","year":"2021","unstructured":"George G, Vikman H, Gedeborg R et al (2021) Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta Oncol 60:459\u2013465. https:\/\/doi.org\/10.1080\/0284186X.2021.1885058","journal-title":"Acta Oncol"},{"key":"6335_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.14744\/AnatolJCardiol.2017.8003","volume":"18","author":"O Gokalp","year":"2017","unstructured":"Gokalp O, Iscan S, Iner H, Gurbuz A (2017) The effects of steroids on endothelial function. Anatol J Cardiol 18:309. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2017.8003","journal-title":"Anatol J Cardiol"},{"key":"6335_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, Lai EC (2019) Taiwan\u2019s National health insurance research database: past and future. Clin Epidemiol 11:349\u2013358. https:\/\/doi.org\/10.2147\/CLEP.S196293","journal-title":"Clin Epidemiol"},{"key":"6335_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","volume":"173","author":"SA Johannesdottir","year":"2013","unstructured":"Johannesdottir SA, Horvath-Puho E, Dekkers OM et al (2013) Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173:743\u2013752. https:\/\/doi.org\/10.1001\/jamainternmed.2013.122","journal-title":"JAMA Intern Med"},{"key":"6335_CR15","doi-asserted-by":"publisher","first-page":"100261","DOI":"10.1016\/j.esmoop.2021.100261","volume":"6","author":"AA Kulkarni","year":"2021","unstructured":"Kulkarni AA, Rubin N, Tholkes A et al (2021) Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. ESMO Open 6:100261. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100261","journal-title":"ESMO Open"},{"key":"6335_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/jnci\/djac081","volume":"114","author":"LY Lai","year":"2022","unstructured":"Lai LY, Oerline MK, Caram MEV, Tsao PA, Kaufman SR, Hollenbeck BK, Shahinian VB (2022) Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer. J Natl Cancer Inst 114:1127\u20131134. https:\/\/doi.org\/10.1093\/jnci\/djac081","journal-title":"J Natl Cancer Inst"},{"key":"6335_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00757-0","author":"YHA Lee","year":"2023","unstructured":"Lee YHA, Hui JMH, Leung CH et al (2023) Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00757-0","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6335_CR18","doi-asserted-by":"publisher","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","volume":"40","author":"LY Lin","year":"2018","unstructured":"Lin LY, Warren-Gash C, Smeeth L, Chen PC (2018) Data resource profile: the National health insurance research database (NHIRD). Epidemiol Health 40:e2018062. https:\/\/doi.org\/10.4178\/epih.e2018062","journal-title":"Epidemiol Health"},{"key":"6335_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaccao.2023.01.001","volume":"5","author":"S Moningi","year":"2023","unstructured":"Moningi S, Nguyen PL (2023) Uncontrolled cardiovascular risk factors in prostate cancer patients: Are we leaving too much on the table? JACC CardioOncol 5:82\u201384. https:\/\/doi.org\/10.1016\/j.jaccao.2023.01.001","journal-title":"JACC CardioOncol"},{"key":"6335_CR20","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/bjh.17388","volume":"193","author":"FA Orsi","year":"2021","unstructured":"Orsi FA, Lijfering WM, Geersing GJ, Rosendaal FR, Dekkers OM, le Cessie S, Cannegieter SC (2021) Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study. Br J Haematol 193:1194\u20131202. https:\/\/doi.org\/10.1111\/bjh.17388","journal-title":"Br J Haematol"},{"key":"6335_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clgc.2023.07.006","volume":"22","author":"F Riekhof","year":"2024","unstructured":"Riekhof F, Yan Y, Bennett CL et al (2024) Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide. Clin Genitourin Cancer 22:18\u201326e13. https:\/\/doi.org\/10.1016\/j.clgc.2023.07.006","journal-title":"Clin Genitourin Cancer"},{"key":"6335_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12904-024-01410-w","volume":"23","author":"U Ronningas","year":"2024","unstructured":"Ronningas U, Holm M, Fransson P, Beckman L, Wennman-Larsen A (2024) Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer\u2014a prospective multicenter study. BMC Palliat Care 23:80. https:\/\/doi.org\/10.1186\/s12904-024-01410-w","journal-title":"BMC Palliat Care"},{"key":"6335_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138\u2013148. https:\/\/doi.org\/10.1056\/NEJMoa1209096","journal-title":"N Engl J Med"},{"key":"6335_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/aje\/kwaa190","volume":"190","author":"LM Scailteux","year":"2021","unstructured":"Scailteux LM, Campillo-Gimenez B, Kerbrat S et al (2021) Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014\u20132018 French population study (the SPEAR Cohort). Am J Epidemiol 190:413\u2013422. https:\/\/doi.org\/10.1093\/aje\/kwaa190","journal-title":"Am J Epidemiol"},{"key":"6335_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bcp.14972","volume":"88","author":"LM Scailteux","year":"2022","unstructured":"Scailteux LM, Despas F, Balusson F et al (2022) Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients. Br J Clin Pharmacol 88:336\u2013346. https:\/\/doi.org\/10.1111\/bcp.14972","journal-title":"Br J Clin Pharmacol"},{"key":"6335_CR26","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"key":"6335_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","volume":"26","author":"MW Schoen","year":"2023","unstructured":"Schoen MW, Carson KR, Eisen SA et al (2023) Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis 26:743\u2013750. https:\/\/doi.org\/10.1038\/s41391-022-00588-5","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6335_CR28","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1378\/chest.12-1446","volume":"143","author":"DJF Stuijver","year":"2013","unstructured":"Stuijver DJF, Majoor CJ, van Zaane B et al (2013) Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest 143:1337\u20131342. https:\/\/doi.org\/10.1378\/chest.12-1446","journal-title":"Chest"},{"key":"6335_CR29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.euf.2016.09.008","volume":"4","author":"HM Westgeest","year":"2018","unstructured":"Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA et al (2018) Differences in trial and real-world populations in the Dutch Castration-resistant prostate cancer registry. Eur Urol Focus 4:694\u2013701. https:\/\/doi.org\/10.1016\/j.euf.2016.09.008","journal-title":"Eur Urol Focus"},{"key":"6335_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrurol.2013.274","volume":"11","author":"L Yin","year":"2014","unstructured":"Yin L, Hu Q (2014) CYP17 inhibitors\u2013abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol 11:32\u201342. https:\/\/doi.org\/10.1038\/nrurol.2013.274","journal-title":"Nat Rev Urol"},{"key":"6335_CR31","doi-asserted-by":"publisher","first-page":"104273","DOI":"10.1016\/j.critrevonc.2024.104273","volume":"196","author":"L Zhen","year":"2024","unstructured":"Zhen L, Juan W, Tianrui F et al (2024) A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately? Crit Rev Oncol Hematol 196:104273. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104273","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06335-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06335-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06335-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:12:21Z","timestamp":1761847941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06335-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6335"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06335-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was granted by the institutional review board of Chang Gung Memorial Hospital (202300400B0C601), which waived the need for informed consent from participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"284"}}